In Section A, contributors will receive various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional individuals are going to be enrolled in the determined monotherapy dosign routine. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase https://abbv-744-in-the-treatment57801.ja-blog.com/32059008/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled